PT - JOURNAL ARTICLE AU - Kerwin, Heather AU - Briggs, Rex AU - Nair-Desai, Sameer AU - Gorzalski, Andrew AU - Pandori, Mark AU - Friedhoff, Stefanie AU - Tsai, Thomas C. TI - An Analysis of SARS-CoV-2 Vaccine Breakthrough Infections and Associated Clinical Outcomes AID - 10.1101/2021.09.09.21262448 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.09.21262448 4099 - http://medrxiv.org/content/early/2021/09/21/2021.09.09.21262448.short 4100 - http://medrxiv.org/content/early/2021/09/21/2021.09.09.21262448.full AB - Understanding the rate and clinical features associated with vaccine breakthrough infections (VBT) is of critical public health importance. Recent evidence on VBT in Barnstable County, Massachusetts, has prompted guidance on masking for vaccinated individuals in areas of high community-level transmission.1 Additional data is needed to better understand the prevalence and rate of VBT infections. Using detailed disease investigation data from Washoe County, Nevada we sought to assess the rate of symptomatic infection and serious illness among VBT cases compared to non-vaccinated individuals with COVID-19. From February 12 - July 29, 2021, the Washoe County Health District identified and traced 6,128 out of 6,399 reported cases across the sample period. 338 (5.5%) of all cases were identified as breakthrough infections, and 289 (86%) vaccinated individuals had symptomatic infections. Severe clinical outcomes were infrequent with 17 hospitalizations (5% of VBT) and no deaths. Cycle threshold values were not statistically different between vaccinated and unvaccinated individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Washoe County Health District and the Nevada State Health Laboratory report funding from the CDC for work unrelated to this manuscript. Thomas Tsai reports funding from William F. Milton Fund of Harvard University, the Massachusetts Consortium on Pathogen Readiness underwritten by the Massachusetts Life Sciences Center, The Commonwealth Fund, and Arnold Ventures for work unrelated to this manuscript. No other disclosures were reported.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Brown University's Institutional Review Board did not classify our study as human subjects research, and thus IRB/HRPP review was not deemed necessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data utilized in this analysis are available upon request from the lead author.